Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Khiron Life Sciences Corp. (V:KHRN)

Business Focus: Alternative Medicine

Oct 07, 2021 07:00 am ET
Khiron Life Sciences Corp.: Invitation to the Benzinga Cannabis Capital Conference
Toronto, Ontario--(Newsfile Corp. - October 7, 2021) - Khiron Life Sciences Corp. (TSXV: KHRN.V) (OTCQX: KHRNF) (FSE: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be participating in the Benzinga Cannabis Capital Conference, which will take place on October 14 and October 15 at the Marriott Marquis hotel in New York City.
Oct 07, 2021 06:00 am ET
Khiron presents its first research study with 1,400 patients
12-month observational study results presented at the International Pain Conference in Colombia on September 25th, 2021
Oct 07, 2021 06:00 am ET
Khiron presents its first research study with 1,400 patients
12-month observational study results presented at the International Pain Conference in Colombia on September 25th, 2021
Oct 04, 2021 04:00 pm ET
Khiron Life Sciences to Present at Upcoming October Investor Conferences
TORONTO, Oct. 4, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual investor conferences in October 2021:
Oct 04, 2021 04:00 pm ET
Khiron Life Sciences to Present at Upcoming October Investor Conferences
TORONTO, Oct. 4, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual investor conferences in October 2021:
Oct 04, 2021 06:00 am ET
Khiron reports medical cannabis prescription growth in South America and Europe
TORONTO, Oct. 4, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations:
Oct 04, 2021 06:00 am ET
Khiron reports medical cannabis prescription growth in South America and Europe
TORONTO, Oct. 4, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations:
Oct 01, 2021 05:40 pm ET
Khiron's Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO
TORONTO, Oct. 1, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of directors has appointed Swapan Kakumanu of RTB LLP to the role of Interim CFO, effective immediately. Mr. Friedman will remain with Khiron until October 31, 2021 to provide transitional support.
Oct 01, 2021 05:40 pm ET
Khiron's Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO
TORONTO, Oct. 1, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of directors has appointed Swapan Kakumanu of RTB LLP to the role of Interim CFO, effective immediately. Mr. Friedman will remain with Khiron until October 31, 2021 to provide transitional support.
Sep 13, 2021 04:15 pm ET
Khiron Receives Approval To Renew Its Normal Course Issuer Bid
TORONTO, Sept. 13, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its September 9, 2021 press release, the Company has received final approval from the TSX Venture Exchange (the "TSXV") to renew its normal course issuer bid to repurchase, for cancellation, up to 8,955,853 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "
Sep 13, 2021 04:15 pm ET
Khiron Receives Approval To Renew Its Normal Course Issuer Bid
TORONTO, Sept. 13, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its September 9, 2021 press release, the Company has received final approval from the TSX Venture Exchange (the "TSXV") to renew its normal course issuer bid to repurchase, for cancellation, up to 8,955,853 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares
Sep 09, 2021 07:00 am ET
Khiron Announces Intention to Renew its Normal Course Issuer Bid
TORONTO, Sept. 9, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF) , (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Exchange (the "TSXV") to repurchase, for cancellation, up to 8,955,893 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB"). The renewal of the NCIB remains subject t
Sep 09, 2021 07:00 am ET
Khiron Announces Intention to Renew its Normal Course Issuer Bid
TORONTO, Sept. 9, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF) , (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Exchange (the "TSXV") to repurchase, for cancellation, up to 8,955,893 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB"). The renewal of the NCIB remains su
Aug 31, 2021 07:00 am ET
Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide
Alixen™ 30 and Alixen™ 100, CBD-rich products, become Khiron's first two registered medical cannabis products, following approval by the Peruvian sanitary agency, DIGEMID Shelf-ready Alixen™ 30 and Alixen™ 100, exported from Colombia, to be broadly distributed throughout pharmacy chains, medical distributors, and dispensaries in Peru starting Q4 2021 Product availability expected to improve service levels for new and existing medical cannabis patients through broader pharmacy distribution network and faster product delivery times Company plans to obtain registration for high-THC product in P
Aug 31, 2021 07:00 am ET
Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide
Alixen™ 30 and Alixen™ 100, CBD-rich products, become Khiron's first two registered medical cannabis products, following approval by the Peruvian sanitary agency, DIGEMID Shelf-ready Alixen™ 30 and Alixen™ 100, exported from Colombia, to be broadly distributed throughout pharmacy chains, medical distributors, and dispensaries in Peru starting Q4 2021 Product availability expected to improve service levels for new and existing medical cannabis patients through broader pharmacy distribution network and faster product delivery times Company plans to obtain registration for high-THC product in P
Aug 23, 2021 07:00 am ET
Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany
Q2 2021 revenues of $2.8 million, up 68% YoY Medical cannabis revenues reach $825,500, up 47% sequentially, with sales in Colombia, Germany, UK, and Peru contributing to gross medical cannabis profit margin of 88% European medical cannabis sales growth of 280% sequentially, representing over 25% of total medical cannabis revenues Medical cannabis expected to become dominant revenue stream, with monthly revenues forecast to increase to over $1 million by Q1 2022, on top of expected $1 million in health services $9.4 million in cash as of June 30,2021, a decrease of $3.2 million from march 31s
Aug 23, 2021 07:00 am ET
Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany
Q2 2021 revenues of $2.8 million, up 68% YoY Medical cannabis revenues reach $825,500, up 47% sequentially, with sales in Colombia, Germany, UK, and Peru contributing to gross medical cannabis profit margin of 88% European medical cannabis sales growth of 280% sequentially, representing over 25% of total medical cannabis revenues Medical cannabis expected to become dominant revenue stream, with monthly revenues forecast to increase to over $1 million by Q1 2022, on top of expected $1 million in health services $9.4 million in cash as of June 30,2021, a decrease of $3.2 million from march 31s
Aug 17, 2021 07:30 am ET
Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021
TORONTO, Aug. 17, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, August 23rd , 2021 at 10:00 a.m. Eastern Time to discuss its results for the second quarter ended June 30, 2021. The Company will press release its financial results prior to the conference call.
Aug 17, 2021 07:30 am ET
Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021
TORONTO, Aug. 17, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, August 23rd , 2021 at 10:00 a.m. Eastern Time to discuss its results for the second quarter ended June 30, 2021. The Company will press release its financial results prior to the conference call.
Aug 11, 2021 07:00 am ET
Khiron Life Sciences Corp.: Invitation to the Q3 Virtual Investor Summit
Toronto, Ontario--(Newsfile Corp. - August 11, 2021) - Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres will be attending the Q3 Virtual Investor Summit.
Aug 10, 2021 07:30 am ET
Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership
TORONTO, Aug. 10, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the release of its inaugural Environmental, Social and Governance (ESG) report, which captures the period between January 1, 2020 and December 31, 2020.
Aug 10, 2021 07:30 am ET
Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership
TORONTO, Aug. 10, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the release of its inaugural Environmental, Social and Governance (ESG) report, which captures the period between January 1, 2020 and December 31, 2020.
Jul 29, 2021 08:30 am ET
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early
Jul 29, 2021 08:30 am ET
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early
Jul 26, 2021 07:00 am ET
Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis
On July 23, 2021, the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal insurance coverage for THC and CBD in late 2020 The decree allows for 1) the expansion of medical cannabis distribution across most pharmacies in the country, 2) the expansion of CBD-based product portfolios within the country, and 3) the export of dried flower medical cannabis
Jul 26, 2021 07:00 am ET
Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis
On July 23, 2021, the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal insurance coverage for THC and CBD in late 2020 The decree allows for 1) the expansion of medical cannabis distribution across most pharmacies in the country, 2) the expansion of CBD-based product portfolios within the country, and 3) the export of dried flower medical cannabis
Jul 08, 2021 11:54 am ET
Khiron Life Sciences Closes $12.3 Million Equity Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Jul 06, 2021 08:48 am ET
Khiron Life Sciences Announces Terms of Overnight Marketed Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 05, 2021 11:36 pm ET
Khiron Life Sciences Announces Proposed Offering of Securities
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 02, 2021 04:30 pm ET
Khiron Announces Results of 2021 Annual General Meeting
Lytham Partners to Provide Investor Relations Services
Jul 02, 2021 04:30 pm ET
Khiron Announces Results of 2021 Annual General Meeting
Lytham Partners to Provide Investor Relations Services
Jul 02, 2021 08:30 am ET
Khiron successfully completes first medical cannabis sale in Brazil
With over 200 million people, Brazil is Latin America´s largest addressable medical cannabis market, with the potential to reach USD$1.4 billion in annual revenue (Source: New Frontier Data) In partnership with leading medical cannabis patient association in Brazil, a child with epilepsy becomes first Brazilian patient to receive Khiron medical cannabis product Khiron plans to expand Zerenia™ vertically integrated clinic model into Brazil, increasing patient access to affordable, high-quality medical cannabis products TORONTO, July 2, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the
Jul 02, 2021 08:30 am ET
Khiron successfully completes first medical cannabis sale in Brazil
With over 200 million people, Brazil is Latin America´s largest addressable medical cannabis market, with the potential to reach USD$1.4 billion in annual revenue (Source: New Frontier Data) In partnership with leading medical cannabis patient association in Brazil, a child with epilepsy becomes first Brazilian patient to receive Khiron medical cannabis product Khiron plans to expand Zerenia™ vertically integrated clinic model into Brazil, increasing patient access to affordable, high-quality medical cannabis products TORONTO, July 2, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron"
Jun 30, 2021 09:26 am ET
Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court's Advancement of Cannabis Laws
Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy Recent regulatory and supply chain advances accelerate the Company's entry into the medical market by several months TORONTO, June 30, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core opera
Jun 30, 2021 09:26 am ET
Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court's Advancement of Cannabis Laws
Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy Recent regulatory and supply chain advances accelerate the Company's entry into the medical market by several months TORONTO, June 30, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with cor
Jun 28, 2021 09:10 am ET
Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia
With a population close to 130 million people, Mexico is among the top 15 economies worldwide and second largest in Latin America. Approximately 11.7 million people have conditions treatable with medical cannabis (Source: IMS Quintiles) Leveraging its Project of National Strategic Interest (PINES) designation, Khiron receives THC extract export quota for Mexico from Colombia, for up to 700 Kg of extract and finished medical product Khiron has finalized agreements for the manufacture and distribution of finished medical cannabis products in Mexico, establishing a key component of its Mexican
Jun 28, 2021 09:10 am ET
Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia
With a population close to 130 million people, Mexico is among the top 15 economies worldwide and second largest in Latin America. Approximately 11.7 million people have conditions treatable with medical cannabis (Source: IMS Quintiles) Leveraging its Project of National Strategic Interest (PINES) designation, Khiron receives THC extract export quota for Mexico from Colombia, for up to 700 Kg of extract and finished medical product Khiron has finalized agreements for the manufacture and distribution of finished medical cannabis products in Mexico, establishing a key component of its Mexican
Jun 14, 2021 05:36 pm ET
Khiron provides European management updates
TORONTO, June 14, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the appointment of Franziska Katterbach as President, Khiron Europe to replace Tejinder Virk, who has resigned from the Company.
Jun 14, 2021 05:36 pm ET
Khiron provides European management updates
TORONTO, June 14, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the appointment of Franziska Katterbach as President, Khiron Europe to replace Tejinder Virk, who has resigned from the Company.
Jun 10, 2021 09:00 am ET
Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients
Company launches first Zerenia™ medical cannabis clinic outside of Colombia, exporting proven clinic model via strategic partnership with Lima-based Clinica Montesur Clinica Montesur is a specialized medical clinic with over 90 doctors covering 19 specialties and 11,000 patient transactions annually; its clinic is centrally located in Lima, Peru, a city of 10 million people or a third of the country's total population Partnership combines Khiron's unique medical cannabis expertise, including the Company's real-world evidence, medical education, best practices and systems, with Clinica Montes
Jun 10, 2021 09:00 am ET
Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients
Company launches first Zerenia™ medical cannabis clinic outside of Colombia, exporting proven clinic model via strategic partnership with Lima-based Clinica Montesur Clinica Montesur is a specialized medical clinic with over 90 doctors covering 19 specialties and 11,000 patient transactions annually; its clinic is centrally located in Lima, Peru, a city of 10 million people or a third of the country's total population Partnership combines Khiron's unique medical cannabis expertise, including the Company's real-world evidence, medical education, best practices and systems, with Clinica Montes
Jun 08, 2021 09:48 am ET
Khiron receives its largest European medical cannabis shipment to date
Khiron's largest shipment to date of EU-GMP certified medical cannabis product arrives in Germany Khiron 20/1, a THC-dominant Cannabis flower, becomes second Khiron-branded product to launch in Germany, having been prescribed in the UK 36.6kg shipment expected to have positive impact on Q2 2021 medical cannabis sales in Europe German medical cannabis market positioned for significant growth with national insurance coverage and an estimated patient base of over 100,000 TORONTO, June 8, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt:
Jun 08, 2021 09:48 am ET
Khiron receives its largest European medical cannabis shipment to date
Khiron's largest shipment to date of EU-GMP certified medical cannabis product arrives in Germany Khiron 20/1, a THC-dominant Cannabis flower, becomes second Khiron-branded product to launch in Germany, having been prescribed in the UK 36.6kg shipment expected to have positive impact on Q2 2021 medical cannabis sales in Europe German medical cannabis market positioned for significant growth with national insurance coverage and an estimated patient base of over 100,000 TORONTO, June 8, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Fra
Jun 01, 2021 08:00 am ET
Khiron Life Sciences Corp.: Invitation to the Benzinga Virtual Cannabis Capital Conference
Detroit, Michigan--(Newsfile Corp. - June 1, 2021) - Khiron Life Sciences Corp. (TSXV: KHRN) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021. We invite our shareholder and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration
May 31, 2021 06:30 pm ET
Khiron Announces Upcoming Investor Events and Grant of Options and Restricted Share Units
TORONTO, May 31, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company´s management will be participating in the following investor:
May 27, 2021 05:00 pm ET
Khiron Life Sciences Reports First Quarter 2021 Financial Results
Record revenues of $2.8 million in Q1 2021, a 49% increase from the prior year and 13% increase from Q4 2020 Record gross profits (before fair market value adjustments) of $1.1 million, a 171% improvement over Q4 2020 and record consolidated gross margin of 38% Medical cannabis sales reach 20% of revenues, contributing over 45% of gross profits More than 7,500 prescriptions filled in Q1 2021 and over 19,000 to date First sales in Germany achieved in Q1 2021, with international sales representing approximately 10% of total Medical Cannabis Product revenues Khiron real-world evidence is impro
May 25, 2021 10:18 am ET
Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations
Khiron and the Colombia Cancer League, together with 21 leading medical institutions in 11 cities throughout Colombia, have co-launched the "Cannabis: Medicine for Your Life" campaign which aims to improve safe access to consultations for medical cannabis Physicians participating in the campaign will donate more than 3,000 consultations, initially available to chronic pain, palliative care and oncology patients As the leading provider of medical cannabis in Colombia, Khiron has filled over 18,000 prescriptions to date, achieving more than 120% growth in medical cannabis prescriptions filled
May 19, 2021 05:30 pm ET
Khiron to Host First Quarter 2021 Conference Call on May 28, 2021
TORONTO, May 19, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Friday, May 28, 2021 at 10:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. The Company will provide its financial results in a press release prior to the conference call.
May 12, 2021 08:00 am ET
Khiron Life Sciences Corp.: Invitation to the Q2 Virtual Investor Summit
Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres will be attending the Q2 Virtual Investor Summit.
May 11, 2021 08:00 am ET
Khiron Comments on the Results of Project Twenty21 - UK´s Largest Observational Study into Medical Cannabis Products
Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette's Syndrome and PTSD Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions TORONTO, May 11, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
May 06, 2021 04:30 pm ET
Khiron to Present at Canaccord Genuity's Virtual Cannabis Conference
TORONTO, May 6, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Chairman Chris Naprawa will present live at Canaccord Genuity's 2021 Virtual Cannabis Conference on Tuesday, May 11, 2021 at 1:00 p.m. EDT (10:00 a.m. PDT).
Apr 29, 2021 06:36 pm ET
Khiron Life Sciences Reports 2020 Fiscal Year End Results and Provides Corporate Update
Generated 31% sequential quarter-on-quarter growth in Q4 2020, driven by normalized clinic operations and more than doubling of medical cannabis sales. Benefited from medical cannabis insurance coverage in Colombia effective December 2020. Insurance coverage continues to be a catalyst for growth in Colombia, with more than 7,500 prescriptions filled in Q1 2021 versus over 3,300 in Q4 2020. Maintained strong domestic pricing, with an average sales price of $58 per unit in Colombia during the fourth quarter. Positioned for growth with sales execution underway in four countries (Colombia, Peru,
Apr 13, 2021 09:30 am ET
Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education
Company has received UK Continuing Professional Development ("CPD") accreditation for its global education platform, Khiron Academy UK medical professionals may now earn CPD credits through Khiron's medical cannabis education program The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy traini
Apr 07, 2021 08:30 am ET
Khiron Expands Product Offering in UK and Increases Patient Access
Following successful medical cannabis launch in Germany, Khiron 1/14, a high CBD flower is expected to be available in Q2/21 for UK patients Khiron plans to introduce additional cannabis-based medical products with its registered strains, recently exported from Colombia to Europe Supply chain improvements will increase availability of medical cannabis for patients in the United Kingdom TORONTO, April 7, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin Ame
Mar 22, 2021 07:30 am ET
Khiron Medical Cannabis Products Arrive in Germany for Immediate Prescription, Sale and Distribution
First shipment of Khiron branded EU-GMP certified medical cannabis to Germany successfully completed, providing immediate access to German market through distribution partner, Nimbus Health GmbH Launch product is Khiron 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis Company to leverage partnership with Nimbus Health GmbH, a leading EU-GMP/GDP certified medical cannabis distributor in Germany with network of over 300 pharmacies Khiron teams continue to educate physi
Mar 18, 2021 07:30 am ET
Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2
Zerenia™ expansion follows successful start to 2021, with paid prescriptions in first 2.5 months of the year exceeding total 2020 prescriptions in Colombia Satellite clinics proving an effective patient acquisition model; in first two months of 2021, a significant number of new paying patients were acquired through Khiron's satellite clinics Khiron recently opened two additional satellite Zerenia™ clinics in major metropolitan centres of Cali and Bucaramanga in Colombia (over 2.5 million population combined), bringing the Company's total health centre and clinic count to six As the Company e
Mar 11, 2021 08:30 am ET
Khiron Life Sciences Corp. To Present At The Q1 Virtual Investor Summit
via InvestorWire - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, CEO, will be attending the...
Mar 11, 2021 06:00 am ET
Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe
Khiron has successfully exported its registered cannabis strains, in the form of live clones, from Colombia to Europe Company is executing on an asset light growth strategy in Europe by working with contract manufacturing and distribution partners to accelerate production and delivery of EU-GMP certified medical cannabis products Company expects to grow its existing European offering by introducing branded extracts and dried flower products, based on those already distributed in Colombia and Peru, with over 13,000 prescriptions written to date By 2024, the European market is expected to be w
Feb 23, 2021 05:30 am ET
Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America
International Diploma in Medicinal Cannabis for Latin American doctors to be hosted virtually through Mexico's TecSalud School of Medicine and Health Sciences (EMCS), beginning February 20, 2021 Physicians from Mexico and across Latin America will participate in a fee-based 6-week diploma program Diploma marks a historic advance in medical education around the prescription of medicinal cannabis in Mexico and the Latin America region Mexico emerges as a key player in the global medical cannabis market following the signing of legislation in January 2021 Khiron plans to build on the success of
Feb 23, 2021 05:30 am ET
Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America
International Diploma in Medicinal Cannabis for Latin American doctors to be hosted virtually through Mexico's TecSalud School of Medicine and Health Sciences (EMCS), beginning February 20, 2021 Physicians from Mexico and across Latin America will participate in a fee-based 6-week diploma program Diploma marks a historic advance in medical education around the prescription of medicinal cannabis in Mexico and the Latin America region Mexico emerges as a key player in the global medical cannabis market following the signing of legislation in January 2021 Khiron plans to build on the success of
Feb 22, 2021 09:31 am ET
Khiron Life Sciences Corp.: Invitation to the Benzinga Virtual Cannabis Capital Conference
Detroit, Michigan--(Newsfile Corp. - February 22, 2021) - Khiron Life Sciences Corp. (TSXV: KHRN) will be presenting at the Benzinga Cannabis Capital Conference taking place on February 25-26, 2021. We invite our shareholder and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration.
Feb 10, 2021 05:30 am ET
Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch
Khiron to launch two additional small-format Zerenia™ clinics in major metropolitan centres outside of Bogota in early March 2021, following successful launch of the Company's first small-format clinic in Medellin in December 2020 New clinics bring Khiron's total number of clinics in Colombia to six, expanding regional access throughout the country, where an estimated 6 million people have conditions that may be treated with medical cannabis (Source: IMS Quintiles) In January, eight of every ten patients obtained a paid prescription at the initial Medellin small-format clinic Small-format cl
Feb 10, 2021 05:30 am ET
Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch
Khiron to launch two additional small-format Zerenia™ clinics in major metropolitan centres outside of Bogota in early March 2021, following successful launch of the Company's first small-format clinic in Medellin in December 2020 New clinics bring Khiron's total number of clinics in Colombia to six, expanding regional access throughout the country, where an estimated 6 million people have conditions that may be treated with medical cannabis (Source: IMS Quintiles) In January, eight of every ten patients obtained a paid prescription at the initial Medellin small-format clinic Small-format cl
Feb 09, 2021 07:00 pm ET
Khiron Announces Grants of Restricted Share Units
TORONTO, Feb. 9, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of restricted share units ("RSUs") under the Company's amended and restated restricted share unit plan approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.
Feb 09, 2021 07:00 pm ET
Khiron Announces Grants of Restricted Share Units
TORONTO, Feb. 9, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of restricted share units ("RSUs") under the Company's amended and restated restricted share unit plan approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.
Feb 04, 2021 05:30 am ET
Khiron Announces Live Webcast and Upcoming Investor Events
TORONTO, Feb. 4, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, along with members of the Khiron management team, will host a live webcast on Wednesday, February 17 at 11:00am ET to discuss recent results and management's outlook for 2021.
Feb 04, 2021 05:30 am ET
Khiron Announces Live Webcast and Upcoming Investor Events
TORONTO, Feb. 4, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, along with members of the Khiron management team, will host a live webcast on Wednesday, February 17 at 11:00am ET to discuss recent results and management's outlook for 2021.
Jan 08, 2021 05:30 am ET
Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference
TORONTO, Jan. 8, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will participate live at the ATB 9th Annual Institutional Investor Conference  being held on January 12-14, 2021 .
Jan 08, 2021 05:30 am ET
Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference
TORONTO, Jan. 8, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will participate live at the ATB 9th Annual Institutional Investor Conference  being held on January 12-14, 2021 .
Dec 23, 2020 05:30 am ET
Khiron Provides Year-End Corporate Update
TORONTO, Dec. 23, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, provides a year-end corporate update on its global operations.
Dec 23, 2020 05:30 am ET
Khiron Provides Year-End Corporate Update
TORONTO, Dec. 23, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, provides a year-end corporate update on its global operations.
Dec 11, 2020 06:00 am ET
Khiron to Present at the 13th Annual LD Micro Main Event Conference
TORONTO, Dec. 11, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on December 14th. Khiron Chairman Chris Naprawa will be presenting to a live, virtual audience.
Dec 11, 2020 06:00 am ET
Khiron to Present at the 13th Annual LD Micro Main Event Conference
TORONTO, Dec. 11, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on December 14th. Khiron Chairman Chris Naprawa will be presenting to a live, virtual audience.
Dec 10, 2020 05:30 am ET
Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia
Khiron High THC medical cannabis product successfully imported into Peru, with first prescriptions to be filled in December through a partnership with Farmacia Universal S.A.C. Khiron is the first company to export High THC medical cannabis from Colombia, and the only Colombian company authorized to fill High THC prescriptions in Peru for commercial purposes Farmacia Universal operates 10 locations across Lima, a metro region with close to 11 million residents, representing almost one third of Peru's total population Expands on sales in Peru of Company's High CBD magistral preparations, whic
Dec 10, 2020 05:30 am ET
Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia
Khiron High THC medical cannabis product successfully imported into Peru, with first prescriptions to be filled in December through a partnership with Farmacia Universal S.A.C. Khiron is the first company to export High THC medical cannabis from Colombia, and the only Colombian company authorized to fill High THC prescriptions in Peru for commercial purposes Farmacia Universal operates 10 locations across Lima, a metro region with close to 11 million residents, representing almost one third of Peru's total population Expands on sales in Peru of Company's High CBD magistral preparations, whic
Dec 07, 2020 08:00 am ET
Khiron Life Sciences Corp Invites You to Join Us at the Benzinga Global Small Cap Conference
Toronto, Ontario--(Newsfile Corp. - December 7, 2020) - Khiron Life Sciences Corp (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020. We invite our shareholders and all interested parties to explore small cap investment opportunities through two days of networking, dealmaking and discovery.
Dec 07, 2020 05:30 am ET
Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia
Khiron applauds Colombia on becoming one of the first countries to extend national health insurance for patients to include medical cannabis as a first line therapy Leveraging Khiron's status as a National Strategic Project, Khiron medical cannabis products and clinic services are now covered by health insurance companies in Colombia Over 94% of Colombians have health insurance policies More than 1,000 Khiron prescriptions issued in the last quarter have already qualified for this insurance coverage, removing economic barriers and increasing patient access to the Company's products and servi
Dec 07, 2020 05:30 am ET
Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia
Khiron applauds Colombia on becoming one of the first countries to extend national health insurance for patients to include medical cannabis as a first line therapy Leveraging Khiron's status as a National Strategic Project, Khiron medical cannabis products and clinic services are now covered by health insurance companies in Colombia Over 94% of Colombians have health insurance policies More than 1,000 Khiron prescriptions issued in the last quarter have already qualified for this insurance coverage, removing economic barriers and increasing patient access to the Company's products and servi
Dec 01, 2020 05:30 am ET
Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia
Khiron's first clinic outside of Bogota, supporting demand for the Company's clinic services and expanding patient access to medical cannabis Opening represents Khiron's fourth clinic in Colombia, enabling direct patient access in Medellin – A region with more than 6 million residents Leverages the proven Zerenia model which to date has attracted 25% of patients from outside of Bogota Medellin clinic to open and begin meeting patient needs in early December 2020 Continues Khiron's satellite clinic expansion strategy, with recently announced Mexican clinic TORONTO, Dec. 1, 2020 /CNW/ - Khiro
Dec 01, 2020 05:30 am ET
Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia
Khiron's first clinic outside of Bogota, supporting demand for the Company's clinic services and expanding patient access to medical cannabis Opening represents Khiron's fourth clinic in Colombia, enabling direct patient access in Medellin – A region with more than 6 million residents Leverages the proven Zerenia model which to date has attracted 25% of patients from outside of Bogota Medellin clinic to open and begin meeting patient needs in early December 2020 Continues Khiron's satellite clinic expansion strategy, with recently announced Mexican clinic TORONTO, Dec. 1, 2020 /PRNewswire/
Nov 30, 2020 05:20 pm ET
Khiron Reports Third Quarter 2020 Financial Results
Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia. Prescriptions filled increased over 450% in Q3 2020 over Q2 2020 Khiron declared a National Strategic Project by the Government of Colombia, simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020, selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD Khiron signed partnerships with 15
Nov 30, 2020 05:20 pm ET
Khiron Reports Third Quarter 2020 Financial Results
Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia. Prescriptions filled increased over 450% in Q3 2020 over Q2 2020 Khiron declared a National Strategic Project by the Government of Colombia, simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020, selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD Khiron signed partnerships with 15
Nov 30, 2020 05:30 am ET
Juan Carlos Echeverry, Former Colombian Minister of Finance and Former CEO of Colombia's Largest Company, Joins Khiron Board of Directors
Distinguished economist and former CEO of Ecopetrol, Colombia's largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500 Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy Adds proven economic and international business experience to boost the global growth of the Khiron business model Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1st TORONTO, Nov. 30, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Fr
Nov 30, 2020 05:30 am ET
Juan Carlos Echeverry, Former Colombian Minister of Finance and Former CEO of Colombia's Largest Company, Joins Khiron Board of Directors
Distinguished economist and former CEO of Ecopetrol, Colombia's largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500 Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy Adds proven economic and international business experience to boost the global growth of the Khiron business model Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1st TORONTO, Nov. 30, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRN
Nov 27, 2020 05:30 am ET
Khiron Plans to Launch Its Zerenia™ Medical Cannabis Clinic Strategy in Mexico; Applauds Mexican Senate Approval of Legislation for Cannabis in Mexico
On November 19, the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally On March 31, 2020, the Company entered into an agreement with Tecnologico de Monterrey, the leading university in Mexico, to educate physicians across Latin America, in advance of the impending regulations in Mexico To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron's medical education program The Company plans to deploy its ZereniaTM medical cannabis clinics and telehe
Nov 27, 2020 05:30 am ET
Khiron Plans to Launch Its Zerenia™ Medical Cannabis Clinic Strategy in Mexico; Applauds Mexican Senate Approval of Legislation for Cannabis in Mexico
On November 19, the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally On March 31, 2020, the Company entered into an agreement with Tecnologico de Monterrey, the leading university in Mexico, to educate physicians across Latin America, in advance of the impending regulations in Mexico To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron's medical education program The Company plans to deploy its ZereniaTM medical cannabis clinics and telehe
Nov 26, 2020 08:56 am ET
Khiron Life Sciences Announces Closing of $14.49 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option
Khiron Life Sciences Corp. (“Khiron” or, the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has closed today its...
Nov 25, 2020 12:16 pm ET
TMX Group, Khiron, C-Suite at The Open
TORONTO, Nov. 25, 2020 /CNW/ - Alvaro Torres, CEO, Khiron Life Sciences Corp. (TSXV: KHRN), shares his company's story in an interview with TMX Group.
Nov 23, 2020 09:00 am ET
Khiron Life Sciences Re-Files Q2 2020 Interim Financial Statements to Correct Comparative Disclosure and Certain Presentation
Khiron Life Sciences Corp. (“Khiron” or, the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for...
Nov 12, 2020 09:35 am ET
Khiron Life Sciences Corp. to Present at the virtual Fall Investor Summit on November 16th-18th
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Khiron Life Sciences Corp. ((TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC)), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.
Nov 09, 2020 11:56 am ET
IIROC Trading Resumption - KHRN
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - Trading resumes in:
Nov 09, 2020 10:16 am ET
Khiron Life Sciences Announces Upsize of Previously Announced Bought Deal Financing to $12.6 Million
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Nov 09, 2020 08:18 am ET
IIROC Trading Halt - KHRN
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 09, 2020 06:21 am ET
Khiron Life Sciences enters into $10 million bought deal financing
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Oct 19, 2020 08:00 am ET
Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer
TORONTO, Oct. 19, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe announced the appointment, effective October 16, of Joel Friedman as CFO following the resignation of Wendy Kaufman, the Company's CFO since July, 2019.  Ms. Kaufman is departing to return to the mining industry where she has spent the greater part of her executive career.
Oct 19, 2020 08:00 am ET
Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer
TORONTO, Oct. 19, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe announced the appointment, effective October 16, of Joel Friedman as CFO following the resignation of Wendy Kaufman, the Company's CFO since July, 2019.  Ms. Kaufman is departing to return to the mining industry where she has spent the greater part of her executive career.
Oct 14, 2020 08:56 am ET
Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference
TORONTO, Oct. 14, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will present live at the Benzinga Virtual Cannabis Capital Conference on October 15, 2020
Oct 14, 2020 08:56 am ET
Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference
TORONTO, Oct. 14, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will present live at the Benzinga Virtual Cannabis Capital Conference on October 15, 2020
Oct 09, 2020 06:10 am ET
Khiron Corporate Update: Company Reports Accelerated Increase in Medical Cannabis Prescriptions
Khiron reaches more than 3,500 medical cannabis prescriptions filled Medical cannabis prescriptions increased by over 450% in Q3, compared to Q2 of 2020 Khiron's clinics exceeded 9,000 monthly patient consultations in September, marking a return to pre-pandemic monthly levels, supported by the launch of telehealth consultations Khiron was declared a National Strategic Project by the Government of Colombia in September, accelerating its ability to register and introduce new SKUs in the medical cannabis and consumer-packaged goods categories Khiron became the first company to sell medical cann
Oct 06, 2020 09:47 am ET
Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite
TORONTO, Oct. 6, 2020 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX) and the Horizons US Marijuana Index ETF ("HMUS":NEO).
Sep 28, 2020 06:55 am ET
Khiron To Present at Canaccord Genuity Virtual US Cannabis Symposium on September 30th
TORONTO, Sept. 28, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and Director, and Chris Naprawa, Khiron Chairman, will present live at Canaccord Genuity's 2020 Virtual US Cannabis Symposium on September 30, 2020.
Sep 24, 2020 01:34 pm ET
Khiron Becomes First Company to Sell Medical Cannabis in Peru, and Surpasses 3,000 Prescriptions in Colombia
First prescriptions for Khiron's medical cannabis in Peru are filled as the Company surpasses 3,000 medical cannabis prescription milestone in Colombia Khiron becomes the first Company to sell and fill medical cannabis prescriptions through private pharmacies in Peru The Company began sales in Peru with full spectrum High CBD supplied by Khiron Colombia and distributed to patients under the previously announced agreement with Farmacia Universal S.A.C. Farmacia Universal is an established pharmacy chain, with 10 locations in Lima Quotas for Khiron's high THC medical cannabis have also been ap
Sep 22, 2020 08:47 am ET
Khiron Declared a National Strategic Project by the Government of Colombia
Status Accelerates Ability to Bring New Products and Services to Market
Sep 11, 2020 04:10 pm ET
Khiron Announces Shareholder Approval of Amended and Restated Option Plan and Restricted Share Unit Plan, and Grants of RSUs
TORONTO, Sept. 11, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the adoption of the Company's amended and restated stock option plan and the Company's amended and restated restricted share unit plan (together, the "Share Compensation Plans").  The Share Compensation Plans were approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020 (the "AGM") and were previously appr
Sep 08, 2020 01:12 pm ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present September 10th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Sep 04, 2020 08:30 am ET
/R E P E A T -- Khiron Enters Exclusive Partnership with RAPPI, Latin America's Largest Home Multi-Vertical App Platform/
Rappi is the largest home multi-Vertical app in Latin America, which received a USD 1 Billion investment from Softbank Group Corp. and Softbank Vision Fund, reaching unicorn status in 2019. Rappi operates in Brazil, Colombia, Mexico, Argentina, Chile, Costa Rica, Uruguay, Ecuador and Peru, which together represent a population of over 600 million people. Rappi's multi-vertical app provides digital banking and payment services, in addition to everything from food to pharmaceutical products, consumer package goods and courier services, with an average of more than 10 million active users month
Sep 03, 2020 11:59 pm ET
Khiron Enters Exclusive Partnership with RAPPI, Latin America's Largest Home Multi-Vertical App Platform
Rappi is the largest home multi-Vertical app in Latin America, which received a USD 1 Billion investment from Softbank Group Corp. and Softbank Vision Fund, reaching unicorn status in 2019. Rappi operates in Brazil, Colombia, Mexico, Argentina, Chile, Costa Rica, Uruguay, Ecuador and Peru, which together represent a population of over 600 million people. Rappi's multi-vertical app provides digital banking and payment services, in addition to everything from food to pharmaceutical products, consumer package goods and courier services, with an average of more than 10 million active users month
Sep 03, 2020 06:50 am ET
Khiron To Present at Live Investor Conference on September 10th
TORONTO, Sept. 3, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that Alvaro Torres, Khiron CEO and Chris Naprawa, Khiron Chairman, will present live at VirtualInvestorConferences.com on September 10, 2020.
Aug 26, 2020 04:10 pm ET
Khiron Announces Restricted Share Unit Grants
TORONTO, Aug. 26, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that it has granted a total of 1,140,000 restricted share units (RSUs) to certain directors and officers of the Company and its subsidiaries under the Company's Amended and Restated RSU Plan. 
Aug 25, 2020 06:45 am ET
Khiron Expands Medical Cannabis E-Learning Platform to UK Market
UK doctors to receive medical cannabis education through Khiron partnership with Medical Cannabis Clinicians Society ("MCCS"), effective Q3 2020 Expands reach of Khiron's globally recognized cloud-based learning platform currently active in universities and institutions in Latin America MCCS is an independent, clinician-led organization sharing guidance to lead the medical cannabis conversation in the UK Program comprises access to Khiron's e-learning modules to help doctors prescribe medical cannabis for priority conditions including chronic pain, anxiety, cancer and epilepsy Program accele
Aug 24, 2020 09:00 am ET
Khiron Reports Second Quarter 2020 Financial Results
Company achieved first High-THC cannabis sales in Colombia, continued focus towards higher margin medical businesses
Aug 10, 2020 08:50 am ET
Khiron Signs First Kuida™ Distribution Deal in Hong Kong
Breakthrough Agreement Brings CBD Skincare Brand to World Leading Asia Pacific Market
Jul 27, 2020 06:55 am ET
Khiron Provides Corporate Update: Surpasses 1,000 Medical Cannabis Patient Prescription Milestone
Company surpasses 1,000 medical cannabis patient prescriptions in Colombia in the first 10 weeks of sales activity, representing a milestone towards meeting patient needs in Latin America and globally Company prudently managing financial resources through reduced expenses and held approximately $20 Million in cash at the end of June 2020, after closing Q1 with $24 Million and Q4 2019 with $36 Million Received authorization for the sale of magistral preparation of high-THC medical cannabis in Colombia, and as a result Khiron is the first and only company to manufacture and sell high-THC medic
Jul 27, 2020 06:55 am ET
Khiron Provides Corporate Update: Surpasses 1,000 Medical Cannabis Patient Prescription Milestone
Company surpasses 1,000 medical cannabis patient prescriptions in Colombia in the first 10 weeks of sales activity, representing a milestone towards meeting patient needs in Latin America and globally Company prudently managing financial resources through reduced expenses and held approximately $20 Million in cash at the end of June 2020, after closing Q1 with $24 Million and Q4 2019 with $36 Million Received authorization for the sale of magistral preparation of high-THC medical cannabis in Colombia, and as a result Khiron is the first and only company to manufacture and sell high-THC medic
Jul 23, 2020 06:55 am ET
Khiron to Commercialize Medical Cannabis in Peru
Khiron has received all necessary licenses and authorizations allowing full spectrum, high-CBD medical cannabis products to be exported from Colombia for import and commercialization in Peru Full spectrum high CBD medical cannabis will be supplied by Khiron Colombia and manufactured and distributed to patients under the previously announced agreement with Farmacia Universal First patient prescriptions anticipated to be filled in Q3 2020 Receipt of import license and corresponding Colombian authorizations complete all requirements for entry into the Peruvian high CBD medical cannabis market E
Jul 23, 2020 06:55 am ET
Khiron to Commercialize Medical Cannabis in Peru
Khiron has received all necessary licenses and authorizations allowing full spectrum, high-CBD medical cannabis products to be exported from Colombia for import and commercialization in Peru Full spectrum high CBD medical cannabis will be supplied by Khiron Colombia and manufactured and distributed to patients under the previously announced agreement with Farmacia Universal First patient prescriptions anticipated to be filled in Q3 2020 Receipt of import license and corresponding Colombian authorizations complete all requirements for entry into the Peruvian high CBD medical cannabis market E
Jul 21, 2020 04:02 pm ET
Khiron Announces Change of Auditor
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), announces that MNP LLP (the “Former Auditor”) have, at the request of the Company, resigned as auditors of the Company, effective July 10,...
Jul 17, 2020 06:55 am ET
Vamos Colombia! Khiron Hosts Live Virtual Medical Facility Tour
Attendees are invited to attend a real-time, interactive tour of Khiron's recently completed Zerenia medical facility
Jul 17, 2020 06:55 am ET
Vamos Colombia! Khiron Hosts Live Virtual Medical Facility Tour
Attendees are invited to attend a real-time, interactive tour of Khiron's recently completed Zerenia medical facility
Jul 02, 2020 07:00 am ET
Khiron Expands EU Footprint, Signing Kuida™ Distribution Deal in Spain
Kuida CBD skincare products to be distributed through 2,350 stores across four drug store health and beauty distributor groups in Spain Deal with Red Yellow Red, a leading cosmetic products master distributor, representing access to a combined 20,000 stores in Spain and Portugal Kuida product training, CBD category education, and brand promotional activity to support drug store distribution Spain represented a total skincare market of €1.5 billion in 2018 and is expected to reach €1.8 billion by 2023 (Source: Euromonitor - Passport) TORONTO, July 2, 2020 /CNW/ - Khiron Life Sciences Corp. (
Jul 02, 2020 07:00 am ET
Khiron Expands EU Footprint, Signing Kuida™ Distribution Deal in Spain
Kuida CBD skincare products to be distributed through 2,350 stores across four drug store health and beauty distributor groups in Spain Deal with Red Yellow Red, a leading cosmetic products master distributor, representing access to a combined 20,000 stores in Spain and Portugal Kuida product training, CBD category education, and brand promotional activity to support drug store distribution Spain represented a total skincare market of €1.5 billion in 2018 and is expected to reach €1.8 billion by 2023 (Source: Euromonitor - Passport) TORONTO, July 2, 2020 /PRNewswire/ - Khiron Life Sciences
Jun 26, 2020 08:35 am ET
Cannabis Industry Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, June 26, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 24th cannabis conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Jun 25, 2020 10:05 am ET
Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales
Khiron partners with Nimbus Health, a leading medical cannabis distributor in Germany, with broad reach into domestic pharmacies First import and sales of Khiron branded EU GMP medical cannabis products are expected in Q3/20 Medical education and marketing activities to begin imminently Germany is the largest medical cannabis market in Europe with €123M of fully reimbursed patient prescriptions in 2019 (source: GKV) By 2028, the German medical cannabis market is predicted to be worth nearly €7.7bn (source: Prohibition Partners) TORONTO, June 25, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khi
Jun 25, 2020 10:05 am ET
Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales
Khiron partners with Nimbus Health, a leading medical cannabis distributor in Germany, with broad reach into domestic pharmacies First import and sales of Khiron branded EU GMP medical cannabis products are expected in Q3/20 Medical education and marketing activities to begin imminently Germany is the largest medical cannabis market in Europe with €123M of fully reimbursed patient prescriptions in 2019 (source: GKV) By 2028, the German medical cannabis market is predicted to be worth nearly €7.7bn (source: Prohibition Partners) TORONTO, June 25, 2020 /PRNewswire/ - Khiron Life Sciences Corp
Jun 24, 2020 07:00 am ET
/C O R R E C T I O N from Source -- Khiron Life Sciences Corp./
In the news release, Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia, issued 24-Jun-2020 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the second bullet point in the subheadline should read "570 tons" rather than "7 tons" as originally issued inadvertently. The complete, corrected release follows:
Jun 24, 2020 07:00 am ET
Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia
Solar park can generate up to 40% of the energy needs at its 5 hectare facility in Doima, Colombia Project demonstrates Khiron's commitment to sustainability by reducing its carbon footprint by approximately 7 tons of CO2 a year, while decreasing operational energy costs TORONTO, June 24, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the completed installation of a state-of-the-art 2,600 panel solar park that will gener
Jun 24, 2020 07:00 am ET
Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia
Solar park can generate up to 40% of the energy needs at its 5 hectare facility in Doima, Colombia Project demonstrates Khiron's commitment to sustainability by reducing its carbon footprint by approximately 7 tons of CO2 a year, while decreasing operational energy costs TORONTO, June 24, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the completed installation of a state-of-the-art 2,600 panel solar park that wil
Jun 22, 2020 02:51 pm ET
Khiron CEO and Board Chair to Participate in Live Webcast on June 24th
TORONTO, June 22, 2020 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, Khiron CEO and director, and Chris Naprawa, Khiron Board Chair and director will present live at VirtualInvestorConferences.com on June 24th.
Jun 22, 2020 08:35 am ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present June 24th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Jun 22, 2020 08:30 am ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present June 24th
NEW YORK, June 22, 2020 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Wednesday, June 24th.   
Jun 22, 2020 07:00 am ET
Khiron CEO and Board Chair to Participate in Live Webcast on June 24th
Individual and institutional investors, as well as advisors and analysts are invited to attend a real-time, interactive presentation on VirtualInvestorConferences.com
Jun 22, 2020 07:00 am ET
Khiron CEO and Board Chair to Participate in Live Webcast on June 24th
Individual and institutional investors, as well as advisors and analysts are invited to attend a real-time, interactive presentation on VirtualInvestorConferences.com
Jun 12, 2020 04:00 pm ET
Khiron Appoints Chris Naprawa to Director, and Chairman of the Board
TORONTO, June 12, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today the appointment of Chris Naprawa as Director and  Chairman of the Board. In transitioning from his current role as President, Chris will continue to guide the Company and Board as Khiron continues its commercialization phase of its medical cannabis business strategy in Latin America and globally. The Company further announces that Michael Beck has resig
Jun 12, 2020 04:00 pm ET
Khiron Appoints Chris Naprawa to Director, and Chairman of the Board
TORONTO, June 12, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today the appointment of Chris Naprawa as Director and  Chairman of the Board. In transitioning from his current role as President, Chris will continue to guide the Company and Board as Khiron continues its commercialization phase of its medical cannabis business strategy in Latin America and globally. The Company further announces that Michael Beck ha
May 28, 2020 04:05 pm ET
Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results
Closed quarter with net working capital of $28.4 million Achieved revenues of $1.9 Million for Q1 2020, improving gross margin by 17% compared to Q1 2019 Achieved first sales in Colombia of low-THC medical cannabis, and subsequent to the quarter, began its first high-THC medical cannabis sales in Colombia on May 19th 2020 Increased revenues from its Kuida® brand by 18% compared to Q1 2019, despite the impact of sales reduction in March due to the COVID-19 pandemic in Colombia and abroad In May 2020, received first medical cannabis prescriptions for UK patients participating in Project Twenty
May 28, 2020 04:05 pm ET
Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results
Closed quarter with net working capital of $28.4 million Achieved revenues of $1.9 Million for Q1 2020, improving gross margin by 17% compared to Q1 2019 Achieved first sales in Colombia of low-THC medical cannabis, and subsequent to the quarter, began its first high-THC medical cannabis sales in Colombia on May 19th 2020 Increased revenues from its Kuida® brand by 18% compared to Q1 2019, despite the impact of sales reduction in March due to the COVID-19 pandemic in Colombia and abroad In May 2020, received first medical cannabis prescriptions for UK patients participating in Project Twenty
May 20, 2020 12:05 am ET
Khiron Begins Sales of First High-THC Medical Cannabis in Colombia
Khiron is the first company to receive authorization to commercialize high-THC medical cannabis magistral preparations from Colombia's National Narcotics Fund Authorization is supplementary to the previously announced high-THC extraction and cultivation quotas from the Colombian Technical Quotas Group Effective immediately, prescriptions will be filled through Company's ILANS clinics, with expanded distribution in Colombia as partner pharmacies receive dispensary permits Company's ILANS clinics are fully authorized to dispense Khiron's high-THC products for various indications including chro
May 20, 2020 12:05 am ET
Khiron Begins Sales of First High-THC Medical Cannabis in Colombia
Khiron is the first company to receive authorization to commercialize high-THC medical cannabis magistral preparations from Colombia's National Narcotics Fund Authorization is supplementary to the previously announced high-THC extraction and cultivation quotas from the Colombian Technical Quotas Group Effective immediately, prescriptions will be filled through Company's ILANS clinics, with expanded distribution in Colombia as partner pharmacies receive dispensary permits Company's ILANS clinics are fully authorized to dispense Khiron's high-THC products for various indications including chro
May 07, 2020 04:05 pm ET
Khiron to Present at Canaccord Genuity's Global Cannabis Virtual Conference
TORONTO, May 7, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that President Chris Naprawa will present live at Canaccord Genuity's 4th Annual Global Cannabis Virtual Conference on Tuesday, May 12, 2020 at 11:40am ET (8:40am PT).
May 07, 2020 04:05 pm ET
Khiron to Present at Canaccord Genuity's Global Cannabis Virtual Conference
TORONTO, May 7, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that President Chris Naprawa will present live at Canaccord Genuity's 4th Annual Global Cannabis Virtual Conference on Tuesday, May 12, 2020 at 11:40am ET (8:40am PT).
May 06, 2020 12:01 am ET
Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21
Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis
May 06, 2020 12:01 am ET
Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21
Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis
May 01, 2020 06:05 pm ET
Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update
Net working capital of $36.4 Million CAD at December 31, 2019 On March 20, 2020 Khiron became the first and only company in Colombia to receive full authorization to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron became the only Company authorized to export THC products Filled first medical cannabis prescriptions ever using cannabis from their fully completed state-of-the-art, 14,000 square foot GMP and ISO 17025 compliant extraction and analysis lab in Ibague, Colombia Opened European operations, and became the exclusive Latin A
May 01, 2020 06:05 pm ET
Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update
Net working capital of $36.4 Million CAD at December 31, 2019 On March 20, 2020 Khiron became the first and only company in Colombia to receive full authorization to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron became the only Company authorized to export THC products Filled first medical cannabis prescriptions ever using cannabis from their fully completed state-of-the-art, 14,000 square foot GMP and ISO 17025 compliant extraction and analysis lab in Ibague, Colombia Opened European operations, and became the exclusive Latin A
Apr 30, 2020 04:01 pm ET
Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil
Exclusive agreement with Medlive, a pharmaceutical and health products distributor with network of over 3,000 clinics and hospitals in southern Brazil Company's medical cannabis products will be marketed through Medlive network of doctor offices, clinics, hospitals and governmental institutions Medical education, marketing activities and sales are planned to start in Q3 2020 Brazil represents the largest addressable market in Latin America with a population of approximately 212 million TORONTO, April 30, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQ
Apr 30, 2020 04:01 pm ET
Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil
Exclusive agreement with Medlive, a pharmaceutical and health products distributor with network of over 3,000 clinics and hospitals in southern Brazil Company's medical cannabis products will be marketed through Medlive network of doctor offices, clinics, hospitals and governmental institutions Medical education, marketing activities and sales are planned to start in Q3 2020 Brazil represents the largest addressable market in Latin America with a population of approximately 212 million TORONTO, April 30, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)
Apr 28, 2020 07:00 am ET
Khiron Provides Update on Filing of its 2019 Year End Results
Company filing date moved from April 29 to estimate of May 1 to allow auditors to complete audit delayed as a result of COVID-19 situation  Filing extension provided by Ontario Securities Commission on March 23, 2020 in response to COVID-19 pandemic TORONTO, April 28, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that it will delay the filing of its audited financial statements and accompanying management's discussion and analysis
Apr 28, 2020 07:00 am ET
Khiron Provides Update on Filing of its 2019 Year End Results
Company filing date moved from April 29 to estimate of May 1 to allow auditors to complete audit delayed as a result of COVID-19 situation  Filing extension provided by Ontario Securities Commission on March 23, 2020 in response to COVID-19 pandemic TORONTO, April 28, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that it will delay the filing of its audited financial statements and accompanying management's discussion and a
Apr 22, 2020 12:01 am ET
Khiron Signs Medical Cannabis Distribution Deal in Colombia With Locatel
Khiron's medical cannabis products to be carried at Locatel's large-format pharmacy locations in Colombia Locatel is an important pharmacy, healthcare products and medical equipment retailer in Colombia with a database of 2 million patients and customers, and experience managing magistral preparations Locatel e-commerce channels enable product deliveries to all markets and territories across Colombia Locatel's operations deemed an essential service in Colombia during COVID-19 pandemic, ensuring continued access to filling and delivery of prescriptions TORONTO, April 22, 2020 /CNW/ - Khiron
Apr 22, 2020 12:01 am ET
Khiron Signs Medical Cannabis Distribution Deal in Colombia With Locatel
Khiron's medical cannabis products to be carried at Locatel's large-format pharmacy locations in Colombia Locatel is an important pharmacy, healthcare products and medical equipment retailer in Colombia with a database of 2 million patients and customers, and experience managing magistral preparations Locatel e-commerce channels enable product deliveries to all markets and territories across Colombia Locatel's operations deemed an essential service in Colombia during COVID-19 pandemic, ensuring continued access to filling and delivery of prescriptions TORONTO, April 22, 2020 /PRNewswire/ -
Apr 03, 2020 07:50 am ET
Khiron to Report 2019 Fiscal Year End Results and Provides Corporate Update
Khiron to report Q4 and Year End Results on April 28, and webcast Q&A will be held the following day Khiron finished the 2019 calendar year with approximately $36 Million CAD in cash and working capital Khiron and its clinics operational during COVID-19 pandemic under an exemption decreed by the Government of Colombia, without any requirement for further authorization Active teleconsultation services complement Khiron's delivery service that is already delivering medical cannabis prescriptions directly to patients' homes Online education program bringing medical cannabis education to 1,5
Apr 03, 2020 07:50 am ET
Khiron to Report 2019 Fiscal Year End Results and Provides Corporate Update
Khiron to report Q4 and Year End Results on April 28, and webcast Q&A will be held the following day Khiron finished the 2019 calendar year with approximately $36 Million CAD in cash and working capital Khiron and its clinics operational during COVID-19 pandemic under an exemption decreed by the Government of Colombia, without any requirement for further authorization Active teleconsultation services complement Khiron's delivery service that is already delivering medical cannabis prescriptions directly to patients' homes Online education program bringing medical cannabis education to 1,5
Mar 31, 2020 06:56 pm ET
Khiron to Educate Physicians on Medical Cannabis Online with Leading Latin American University
Agreement with Tecnologico de Monterrey, a leading Latin American university (Third Ranked in Latin America) in Mexico brings Khiron´s online education program to reach 1,500 physicians, healthcare practitioners and beyond
Mar 31, 2020 06:56 pm ET
Khiron to Educate Physicians on Medical Cannabis Online with Leading Latin American University
Agreement with Tecnologico de Monterrey, a leading Latin American university (Third Ranked in Latin America) in Mexico brings Khiron´s online education program to reach 1,500 physicians, healthcare practitioners and beyond
Mar 30, 2020 08:21 pm ET
Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia
Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company's 120,000 patients from its ILANS and Zerenia clinics Khrion has already received initial approvals from third party payers to include teleconsultation services in its insured service offerings Khiron and its clinics continue to be operational during COVID-19 pandemic under an exemption decreed by the Government of
Mar 30, 2020 08:21 pm ET
Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia
Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company's 120,000 patients from its ILANS and Zerenia clinics Khrion has already received initial approvals from third party payers to include teleconsultation services in its insured service offerings Khiron and its clinics continue to be operational during COVID-19 pandemic under an exemption decreed by the Government of
Mar 26, 2020 07:00 am ET
OTC Markets Group Welcomes Khiron Life Sciences Corp. to OTCQX
NEW YORK, March 26, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Khiron Life Sciences Corp (TSX-V: KHRN; OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America, has qualified to trade on the OTCQX® Best Market. Khiron Life Sciences Corp. upgraded to OTCQX from the OTCQB® Venture Market.
Mar 20, 2020 09:04 am ET
IIROC Trading Resumption - KHRN
VANCOUVER, March 20, 2020 /CNW/ - Trading resumes in:
Mar 20, 2020 08:48 am ET
Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update
Effective immediately, Khiron is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron anticipates filling its first revenue generating patient prescriptions within days With successful lab certification, Khiron becomes the first company authorized to sell medical cannabis in Colombia Colombia has upwards of 6 million potential patients for medical cannabis products (Source: IMS Quintiles) Khiron also provides a general corporate update and response to Covid-19 TORONTO, March 20, 2020 /CNW/ - Khiron Life Sciences Co
Mar 20, 2020 08:48 am ET
Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update
Effective immediately, Khiron is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron anticipates filling its first revenue generating patient prescriptions within days With successful lab certification, Khiron becomes the first company authorized to sell medical cannabis in Colombia Colombia has upwards of 6 million potential patients for medical cannabis products (Source: IMS Quintiles) Khiron also provides a general corporate update and response to Covid-19 TORONTO, March 20, 2020 /PRNewswire/ - Khiron Life Scie
Mar 19, 2020 02:49 pm ET
IIROC Trading Halt - KHRN
VANCOUVER, March 19, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 05, 2020 05:36 pm ET
Khiron Poised to Enter Medical Cannabis Market in Peru
Signed a 2-year exclusive agreement to manufacture and distribute Khiron-branded medical cannabis products in Lima, Peru´s largest city with 8.6 million inhabitants With 10 locations in Lima, Farmacia Universal S.A.C. is an established magistral formulation laboratory and pharmacy Khiron Perú SA has already obtained certifications as a Pharmaceutical Entity with Good Storage Practices (GSP), a crucial prerequisite for import and commercialization license applications in Peru The Company obtained approval of its security protocols from the Anti-Narcotics Unit of the Ministry of Interior (DIRA
Mar 03, 2020 06:30 am ET
Khiron President Chris Naprawa To Present at 2020 LD Micro Virtual Conference
TORONTO, ON / ACCESSWIRE / March 3, 2020 / Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced today that the Company will be presenting at the third annual LD Micro Virtual Conference on Tuesday March 3rd at 1:40pm PST/4:40pm EST.
Mar 01, 2020 07:56 pm ET
Khiron is First Company Authorized to Extract High THC Medical Cannabis in Colombia
Further to cultivation quotas announced on February 26, 2020, this authorization by the Colombian Technical Quotas Authority ("TQG") allows the Company to now produce oils for sale both domestically and abroad. Of the 9.3 tonnes approved, 50% are for Colombian domestic use and 50% are allowed for export purposes. Export quotas allow for the manufacture of whole plant extract for international purposes to countries such as Peru, Uruguay and Brazil, thereby accessing to a medical cannabis market of $1.4 Billion. (Source: New Frontier Data) Domestic quotas represent a further milestone in the C
Feb 27, 2020 06:21 pm ET
Khiron Receives Approval of Normal Course Issuer Bid
TORONTO, Feb. 27, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN), (OTCQB:KHRNF), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its February 11, 2020 press release, the Company has received final approval from the TSX Venture Exchange (the "TSXV") for a normal course issuer bid to repurchase, for cancellation, up to 5,830,615 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB").
Feb 26, 2020 04:53 pm ET
Khiron Granted Approval to Cultivate 9.3 Tons of THC Cannabis, Representing 17% of the Total Allocated Quota for Colombia in 2020
Colombia was granted a total production quota of 56.2 tons of medical cannabis for 2020 by the International Narcotics Control Board ("INCB"), the entity responsible for the implementation of the United Nations drug conventions. This represents 21.9% of the world´s legal global supply of high THC medical cannabis. The Company will begin cultivation activities immediately in its existing state-of-the-art facility near Ibague, Colombia, with its already-registered strains. The Company will be notified of the accompanying extraction quota by the Ministry of Health of Colombia, which will define
Feb 20, 2020 07:04 am ET
Khiron Announces Plans to Expand Kuida® Distribution to Spain
Company prepares to bring Kuida CBD brand to Spain with receipt of "no objection" letter from TSXV, subject to complying with all regulatory requirements in Spain As previously announced, Khiron has fulfilled E.U. cosmetic product regulatory requirements for seven Kuida products Expands on previously announced Kuida entry to the UK Company further prepares for Kuida to enter the Swiss market, conditional on TSXV approval, representing a skincare market of US$540 million in 2018 (Source: Euromonitor) Spain skincare market estimated at US$1.7 billion in 2019 (Source: Euromonitor) TORONTO, Feb
Feb 14, 2020 06:00 am ET
Khiron to Participate in 3rd Annual Gravitas Growth Conference in Vancouver, BC
TORONTO, Feb. 14, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce it will be participating in the 3rd Annual Gravitas Growth Conference taking place February 20th, 2020 at the Fairmont Pacific Rim Hotel in Vancouver, BC. 
Feb 11, 2020 06:00 am ET
Khiron Announces Normal Course Issuer Bid
TORONTO, Feb. 11, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN), (OTCQB:KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces today its intention to commence a normal course issuer bid through the facilities of the TSX Venture Exchange (the "TSXV") to repurchase, for cancellation, up to 5,830,615 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB"). The NCIB remains subject to the final approval of the TSXV.
Feb 10, 2020 03:30 pm ET
Khiron to Host Investor Webcast Live on February 11, 2020
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations
Feb 07, 2020 06:37 am ET
Brazil Health Agency Authorizes Import of Khiron Medical Cannabis Product
Authorization from the Brazilian Health Regulatory Agency (ANVISA) allows for Khiron medical cannabis product to be imported for use on an individual patient basis Authorization follows December 2019 announcement by ANVISA allowing for a new class of medical cannabis-based product to be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access In Colombia, Company prepares for final authorization milestone allowing for domestic medical cannabis distribution Brazil represents the largest addressable market in Latin America with an anticipated 3.4 million patien
Jan 13, 2020 11:05 pm ET
Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic
Innovative clinic establishes new patient-first model for Colombia with the benefits of complementary professional medical services in a single, integrated care environment Clinic features contemporary design across four expansive floors, within 600 metres of Bogota's largest transit hub, and in the city's prime medical services district 15,000 sq. ft clinic offers comprehensive suite of health and medical services in alignment with insurance company partners Zerenia launch follows the successful growth of Company's Ilans neurological clinics Zerenia branded clinic in keeping with Khiron's p
Jan 05, 2020 11:01 pm ET
Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor Conference
TORONTO, Jan. 6, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that CEO and Director Alvaro Torres will speak on the International Expansion panel at the AltaCorp/ATB 8th Annual Institutional Investor Conference at 3:10pm on January 14, 2020. Mr. Torres and other members of the Khiron leadership team will also be conducting one-on-one meetings at the conference, taking place January 14-16, 2020 at the Shangri-La Hotel Toronto.
Dec 29, 2019 11:01 pm ET
Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis
Khiron the only LP with a 2019 quota that authorizes the Company to manufacture high-THC whole plant extract and produce customized medical cannabis prescriptions for domestic use 56.5 tons, or 21.84% of global supply of high THC medical cannabis for commercial and scientific purposes assigned to Colombia for 2020 by International Narcotics Control Board ("INCB"), the entity responsible for the implementation of the United Nations drug conventions This permit represents the highest annual cannabis quota in Colombian history, and the world's second largest allocations for 2020, based on a tot
Dec 15, 2019 11:01 pm ET
Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification
Peruvian authorities to allow businesses to begin applications for medical cannabis licenses, and further outline a clear licensing process Khiron has secured Good Storage Practices (GSP) certification, a crucial prerequisite for import and commercialization license applications in Peru Company has submitted its security protocols for regulatory review as a further step to securing key licenses With a population of 32 million, Peru's medical cannabis market is estimated to be worth $99 million (Prohibition Partners) Strong cash balance firmly positions Company to capitalize on emerging marke
Dec 03, 2019 11:01 pm ET
Khiron Welcomes Legalization of Medical Cannabis in Brazil
Brazil represents the largest addressable market in Latin America with a population of 208 million and a potential USD $229 Million patient network for medical cannabis (New Frontier Data) Brazilian national health authority (ANVISA) approves the sale of medical cannabis products for sale by prescription and through pharmacies Khiron to participate in Brazil medical cannabis market through the Mercosur Regional Trading Bloc Regulations come into force 90 days after imminent posting on Federal Official Gazette TORONTO, Dec. 4, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Compan
Nov 29, 2019 04:00 pm ET
Khiron Announces Chairman Transition and Appointment of Audit Committee Chair
TORONTO, Nov. 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediately.
Nov 27, 2019 04:30 pm ET
Khiron Announces Option and Restricted Share Unit Grants
TORONTO, Nov. 27, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced that it has granted stock options and restricted share units (RSUs) to certain directors and officers of the Company and its subsidiaries under the Company's Amended and Restated Stock Option Plan and Amended and Restated RSU Plan. 
Nov 26, 2019 06:00 am ET
Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue
Ended the quarter with $47.9 million in cash and short-term investments Robust balance sheet puts Company in a position of strength ILANS clinics showed progressively stronger margins and an over 20% increase in revenues in Q3 Multi-country strategy advances with TSX-V approval for distribution and sale of Kuida CBD products in the United States, with sales launched in the US market in November, and;   Approval to sell Aceso hemp CBD brand in Colombia, targeted for entry in Q1 2020 Fulfilled European Union cosmetic product regulatory requirements for seven Kuida products for distribution int
Nov 24, 2019 11:01 pm ET
Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales
Authorization for domestic and export purposes comes as a result of commercial quotas allocated to Khiron by the Colombian Technical Quotas Group ("TQG") for 2019 Permits Company to cultivate and commercialize psychoactive cannabis Includes authorization to export of whole plant extract to Uruguay and Brazil Positions Khiron to as the first LP to manufacture high-THC whole plant extract and produce customized medical cannabis prescriptions for domestic use TORONTO, Nov. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC)
Nov 20, 2019 11:01 pm ET
Khiron Director and 55th President of Mexico, Vicente Fox to Present Keynote at UK Cannabis Investor Conference
TORONTO, Nov. 21, 2019 /CNW/ -  Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Company Director and 55th President of Mexico, Vicente Fox, will present a keynote address at the Bryan, Garnier & Co Cannabis Conference, taking place on Thursday, November 28, 2019 in London, UK.
Nov 18, 2019 11:01 pm ET
Khiron to be Exclusive Latin American Provider to Project Twenty21, Europe's Largest Medical Cannabis Study with 20,000 Patients
Khiron Life Sciences establishes early mover position to build its brand and product offering in the United Kingdom's nascent medical cannabis market Project Twenty21 will study medical cannabis's therapeutic effects on 20,000 patients - and build largest ever evidence base for UK National Health Service (NHS) provision of these medicines Real-world data registry will document patient outcomes in those prescribed medical cannabis and support health authority applications Project welcomed by The Royal College of Psychiatrists, peers, The British Pain Society, United Patients Alliance and lead
Nov 17, 2019 11:01 pm ET
Khiron Launches Kuida Brand in the US, Begins First Sales
First retail sales in US commence in beauty capital of Los Angeles on November 20, targeting US skincare market Initial distribution to include partnership with leading lifestyle media and retail brand Cannabis Now Activation at Cannabis Now's high-traffic Los Angeles location to target affluent, trendy audience of beauty and cannabis consumers Company to support sales through comprehensive marketing and branding campaign, including content to reach Cannabis Now's 4.2M audience Launch to kick off with experiential event on Nov. 20 at Cannabis Now flagship store US skincare market estimated a
Nov 10, 2019 11:01 pm ET
Khiron Receives Approval to Sell Aceso™ Hemp CBD Brand in Colombia
First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture Builds on proven Aceso brand acceptance across US consumer market Product line includes indication-specific (heat and cool), hemp-derived CBD balms Approval secured from INVIMA for commercialization in Colombia of initial Aceso products, Alfa Balm (heat) and Sigma Balm (cool) Introduction to Colombian market in Q4 2019 with expansion to Chile and Uruguay in 2020 Latin America herbal/traditional topical analgesic and topical analgesics/Anaesthetic market estimated at US$380 million (Source: Euromonitor 2018)
Nov 10, 2019 11:01 pm ET
Khiron Receives Approval to Sell Aceso™ Hemp CBD Brand in Colombia
First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture Builds on proven Aceso brand acceptance across US consumer market Product line includes indication-specific (heat and cool), hemp-derived CBD balms Approval secured from INVIMA for commercialization in Colombia of initial Aceso products, Alfa Balm (heat) and Sigma Balm (cool) Introduction to Colombian market in Q4 2019 with expansion to Chile and Uruguay in 2020 Latin America herbal/traditional topical analgesic and topical analgesics/Anaesthetic market estimated at US$380 million (Source: Euromonitor 2018)
Nov 05, 2019 11:01 pm ET
Khiron Enters First Latin American Cannabis Lines of Research Targeting U.S. $44 Billion Dermatological Drug Market
Clinical research partnership with Centro Dermatológico Federico Lleras Acosta (CDFLLA), focuses on effectiveness of medical cannabis for dermatological conditions defined in three main lines of research: Melanoma, Keratinocytes and Mycobacterial growth. Lines of research presented November 2, 2019 at II TeraCILAD dermatological conference with more than 1,000 LATAM dermatologists in attendance. Research initiated by Khiron and CDFLLA anticipated to begin in Q1 2020, representing first of its kind in Latin America Global dermatological (prescription) drug market valued at $38.4bn in 2017, ri
Nov 05, 2019 11:01 pm ET
Khiron Enters First Latin American Cannabis Lines of Research Targeting U.S. $44 Billion Dermatological Drug Market
Clinical research partnership with Centro Dermatológico Federico Lleras Acosta (CDFLLA), focuses on effectiveness of medical cannabis for dermatological conditions defined in three main lines of research: Melanoma, Keratinocytes and Mycobacterial growth. Lines of research presented November 2, 2019 at II TeraCILAD dermatological conference with more than 1,000 LATAM dermatologists in attendance. Research initiated by Khiron and CDFLLA anticipated to begin in Q1 2020, representing first of its kind in Latin America Global dermatological (prescription) drug market valued at $38.4bn in 2017, ri
Nov 03, 2019 11:01 pm ET
Khiron Appoints Veteran Independent Director Deborah Rosati FCPA, FCA, ICD.D
TORONTO, Nov. 4, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the Company and that Deborah Rosati FCPA, FCA, ICD.D has been appointed effective immediately to the Board of Directors of the Company. Ms. Rosati has over 30 years of experience in leading and managing high growth companies and joins the Board, effective immediately.
Nov 03, 2019 11:01 pm ET
Khiron Appoints Veteran Independent Director Deborah Rosati FCPA, FCA, ICD.D
TORONTO, Nov. 4, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the Company and that Deborah Rosati FCPA, FCA, ICD.D has been appointed effective immediately to the Board of Directors of the Company. Ms. Rosati has over 30 years of experience in leading and managing high growth companies and joins the Board, effective immediately.
Nov 01, 2019 12:01 am ET
Khiron To Participate in Cowen 2nd Annual Boston Cannabis Conference
Company will present to institutional investors and join panel discussions covering developments in the cannabis industry
Nov 01, 2019 12:01 am ET
Khiron To Participate in Cowen 2nd Annual Boston Cannabis Conference
Company will present to institutional investors and join panel discussions covering developments in the cannabis industry
Oct 31, 2019 12:01 am ET
Khiron to Host Live Investor Webcast on November 5, 2019
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentation
Oct 31, 2019 12:01 am ET
Khiron to Host Live Investor Webcast on November 5, 2019
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentation
Oct 25, 2019 12:01 am ET
Kuida is One Year Old! First Export to the US market, UK Product Approval, and 300+ Points of Sale in Colombia
First import of Kuida products into the US now completed, with launch and sales to start in November 2019 E.U. cosmetic product regulatory requirements fulfilled for seven Kuida products, with commercialization in U.K. set for Q1 2020 New distribution agreements secured in Colombia, bringing total points-of-sale to 300+ Multi-channel distribution strategy rapidly advances to target US$135 billion global skincare market TORONTO, Oct. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis lea
Oct 25, 2019 12:01 am ET
Kuida is One Year Old! First Export to the US market, UK Product Approval, and 300+ Points of Sale in Colombia
First import of Kuida products into the US now completed, with launch and sales to start in November 2019 E.U. cosmetic product regulatory requirements fulfilled for seven Kuida products, with commercialization in U.K. set for Q1 2020 New distribution agreements secured in Colombia, bringing total points-of-sale to 300+ Multi-channel distribution strategy rapidly advances to target US$135 billion global skincare market TORONTO, Oct. 25, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated canna
Oct 16, 2019 12:30 am ET
Khiron Participates in Mexican Senate Cannabis Regulation Forum
Mexico poised to become the largest market in the world to fully legalize cannabis nationwideForum with industry leaders to guide legislation to legalize both adult-use and medical cannabis in Mexico – currently expected by the end of October 2019Builds on Khiron's history of leadership and advocacy in Mexico's developing cannabis industry Company holds close relationships with key stakeholders in Mexico, including former president of Mexico and current Khiron board member Vicente Fox, as well as medical associations across the country Company positioned to play a leading role in the Mexican